

**Supplementary Table 1:** Reported doses of intranasally applied adjuvants.

CpG	CT (holotoxin)	CTB	$\alpha$ GalCer	PLGA (loaded, s.c. and i.p.)
50 $\mu$ g <sup>1</sup> 30 $\mu$ g <sup>2</sup> 10 $\mu$ g <sup>3, 4</sup> 1 $\mu$ g <sup>5</sup>	2 $\mu$ g <sup>2, 6</sup> 1 $\mu$ g <sup>1</sup>	10 $\mu$ g <sup>7, 8</sup> 3 $\mu$ g <sup>9</sup> 2 $\mu$ g <sup>2</sup>	2 $\mu$ g <sup>10, 11</sup> 0.3 $\mu$ g <sup>12</sup>	2.5 mg <sup>13</sup>

## Table S1 references:

- Fahlen-Yrliid, L. et al. CD11c(high) dendritic cells are essential for activation of CD4+ T cells and generation of specific antibodies following mucosal immunization. *J Immunol* **183**, 5032-5041 (2009).
- Lee, J.B., Jang, J.E., Song, M.K. & Chang, J. Intranasal delivery of cholera toxin induces th17-dominated T-cell response to bystander antigens. *PLoS One*. **4**, e5190. Epub 2009 Apr 5110. (2009).
- Gallichan, W.S. et al. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. *J Immunol*. **166**, 3451-3457. (2001).
- Lu, B. et al. Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice. *Immunology* **130**, 254-261 (2010).
- McCluskie, M.J. & Davis, H.L. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. *J Immunol* **161**, 4463-4466 (1998).
- Eriksson, A.M., Schon, K.M. & Lycke, N.Y. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. *J Immunol* **173**, 3310-3319 (2004).
- Moschos, S.A., Bramwell, V.W., Somavarapu, S. & Alpar, H.O. Adjuvant synergy: the effects of nasal coadministration of adjuvants. *Immunol Cell Biol* **82**, 628-637 (2004).
- Prabakaran, M. et al. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. *Virology* **380**, 412-420 (2008).
- Quan, F.S. et al. Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. *J Virol* **83**, 4489-4497 (2009).
- Courtney, A.N. et al. Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens. *Vaccine* **27**, 3335-3341 (2009).
- Lindqvist, M., Persson, J., Thorn, K. & Harandi, A.M. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. *J Immunol*. **182**, 6435-6443. (2009).
- Miller, D.S. et al. Preclinical efficacy studies of influenza A haemagglutinin precursor cleavage loop peptides as a potential vaccine. *J Gen Virol* **92**, 1152-1161 (2011).
- Sharp, F.A. et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. *Proc Natl Acad Sci U S A* **106**, 870-875 (2009).